Tandem Diabetes Net Worth
Tandem Diabetes Net Worth Breakdown | TNDM |
Tandem Diabetes Net Worth Analysis
Tandem Diabetes' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tandem Diabetes' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tandem Diabetes' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tandem Diabetes' net worth analysis. One common approach is to calculate Tandem Diabetes' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tandem Diabetes' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tandem Diabetes' net worth. This approach calculates the present value of Tandem Diabetes' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tandem Diabetes' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tandem Diabetes' net worth. This involves comparing Tandem Diabetes' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tandem Diabetes' net worth relative to its peers.
Enterprise Value |
|
To determine if Tandem Diabetes is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tandem Diabetes' net worth research are outlined below:
| Tandem Diabetes Care generated a negative expected return over the last 90 days | |
| Tandem Diabetes Care has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 940.2 M. Net Loss for the year was (96.03 M) with profit before overhead, payroll, taxes, and interest of 489.57 M. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Dexcom shares 15-day CGM data Tandem posts Type 2 pivotal data |
Tandem Diabetes uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tandem Diabetes Care. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tandem Diabetes' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tandem Diabetes Target Price Consensus
Tandem target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Tandem Diabetes' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 22 | Strong Buy |
Most Tandem analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Tandem stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Tandem Diabetes Care, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTandem Diabetes Target Price Projection
Tandem Diabetes' current and average target prices are 20.29 and 51.10, respectively. The current price of Tandem Diabetes is the price at which Tandem Diabetes Care is currently trading. On the other hand, Tandem Diabetes' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Tandem Diabetes Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Tandem Diabetes Target Price
Know Tandem Diabetes' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tandem Diabetes is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tandem Diabetes Care backward and forwards among themselves. Tandem Diabetes' institutional investor refers to the entity that pools money to purchase Tandem Diabetes' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Champlain Investment Partners, Llc | 2024-12-31 | 1.4 M | Hood River Capital Management Llc | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 1.1 M | Chicago Capital Llc | 2024-12-31 | 970.6 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 950.9 K | Gilder Gagnon Howe & Co Llc | 2024-12-31 | 931.9 K | Brown Advisory Holdings Inc | 2024-12-31 | 913.1 K | Paradice Investment Management Llc | 2024-09-30 | 903.4 K | Two Sigma Advisers, Llc | 2024-12-31 | 881.8 K | Blackrock Inc | 2024-12-31 | 11.7 M | Vanguard Group Inc | 2024-12-31 | 7.4 M |
Follow Tandem Diabetes' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.37 B.Market Cap |
|
Project Tandem Diabetes' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.36) | (0.35) |
When accessing Tandem Diabetes' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tandem Diabetes' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tandem Diabetes' profitability and make more informed investment decisions.
Evaluate Tandem Diabetes' management efficiency
Tandem Diabetes Care has return on total asset (ROA) of (0.0645) % which means that it has lost $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.1. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Tandem Diabetes' Total Assets are very stable compared to the past year. As of the 22nd of March 2025, Non Current Assets Total is likely to grow to about 255.3 M, while Intangible Assets are likely to drop about 878.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.02 | 3.82 | |
| Tangible Book Value Per Share | 4.01 | 3.81 | |
| Enterprise Value Over EBITDA | (27.86) | (29.26) | |
| Price Book Value Ratio | 8.96 | 4.89 | |
| Enterprise Value Multiple | (27.86) | (29.26) | |
| Price Fair Value | 8.96 | 4.89 | |
| Enterprise Value | 2 B | 2.2 B |
Management at Tandem Diabetes Care focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 1.4953 | Revenue | Quarterly Revenue Growth 0.436 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tandem Diabetes insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tandem Diabetes Corporate Filings
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 26th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Tandem Diabetes Earnings Estimation Breakdown
The calculation of Tandem Diabetes' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Tandem Diabetes is estimated to be -0.597 with the future projection ranging from a low of -0.67 to a high of -0.45. Please be aware that this consensus of annual earnings estimates for Tandem Diabetes Care is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.67 Lowest | Expected EPS | -0.45 Highest |
Tandem Diabetes Earnings Projection Consensus
Suppose the current estimates of Tandem Diabetes' value are higher than the current market price of the Tandem Diabetes stock. In this case, investors may conclude that Tandem Diabetes is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Tandem Diabetes' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 22 | 70.69% | -0.4356 | -0.597 | -1.47 |
Tandem Diabetes Earnings per Share Projection vs Actual
Actual Earning per Share of Tandem Diabetes refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Tandem Diabetes Care predict the company's earnings will be in the future. The higher the earnings per share of Tandem Diabetes, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Tandem Diabetes Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Tandem Diabetes, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Tandem Diabetes should always be considered in relation to other companies to make a more educated investment decision.Tandem Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Tandem Diabetes' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-19 | 2024-12-31 | -0.2357 | -0.4356 | -0.1999 | 84 | ||
2024-11-06 | 2024-09-30 | -0.4 | -0.35 | 0.05 | 12 | ||
2024-08-01 | 2024-06-30 | -0.54 | -0.48 | 0.06 | 11 | ||
2024-05-02 | 2024-03-31 | -0.76 | -0.63 | 0.13 | 17 | ||
2024-02-21 | 2023-12-31 | -0.25 | -0.27 | -0.02 | 8 | ||
2023-11-01 | 2023-09-30 | -0.34 | -0.38 | -0.04 | 11 | ||
2023-08-03 | 2023-06-30 | -0.53 | -0.55 | -0.02 | 3 | ||
2023-05-03 | 2023-03-31 | -0.52 | -1.92 | -1.4 | 269 | ||
2023-02-22 | 2022-12-31 | -0.06 | -0.25 | -0.19 | 316 | ||
2022-11-02 | 2022-09-30 | -0.05 | -0.27 | -0.22 | 440 | ||
2022-08-03 | 2022-06-30 | 0.02 | -0.24 | -0.26 | 1300 | ||
2022-05-04 | 2022-03-31 | -0.07 | -0.23 | -0.16 | 228 | ||
2022-02-22 | 2021-12-31 | 0.21 | 0.16 | -0.05 | 23 | ||
2021-11-03 | 2021-09-30 | 0.06 | 0.09 | 0.03 | 50 | ||
2021-08-04 | 2021-06-30 | -0.08 | 0.06 | 0.14 | 175 | ||
2021-05-05 | 2021-03-31 | -0.16 | -0.08 | 0.08 | 50 | ||
2021-02-24 | 2020-12-31 | 0.12 | 0.22 | 0.1 | 83 | ||
2020-11-05 | 2020-09-30 | -0.1 | -0.15 | -0.05 | 50 | ||
2020-07-30 | 2020-06-30 | -0.24 | -0.45 | -0.21 | 87 | ||
2020-04-30 | 2020-03-31 | -0.17 | -0.25 | -0.08 | 47 | ||
2020-02-24 | 2019-12-31 | -0.05 | 0.04 | 0.09 | 180 | ||
2019-11-04 | 2019-09-30 | -0.2 | -0.05 | 0.15 | 75 | ||
2019-08-01 | 2019-06-30 | -0.25 | -0.03 | 0.22 | 88 | ||
2019-04-30 | 2019-03-31 | -0.3 | -0.4 | -0.1 | 33 | ||
2019-02-26 | 2018-12-31 | -0.2 | 0.02 | 0.22 | 110 | ||
2018-11-01 | 2018-09-30 | -0.33 | -0.62 | -0.29 | 87 | ||
2018-07-30 | 2018-06-30 | -0.35 | -1.17 | -0.82 | 234 | ||
2018-04-26 | 2018-03-31 | -0.59 | -1.03 | -0.44 | 74 | ||
2018-03-01 | 2017-12-31 | -1.3 | -1.22 | 0.08 | 6 | ||
2017-10-26 | 2017-09-30 | -3.74 | -3.59 | 0.15 | 4 | ||
2017-07-27 | 2017-06-30 | -4.75 | -4.3 | 0.45 | 9 | ||
2017-04-27 | 2017-03-31 | -6.31 | -7.7 | -1.39 | 22 | ||
2017-03-08 | 2016-12-31 | -6.49 | -5.55 | 0.94 | 14 | ||
2016-11-01 | 2016-09-30 | -5.82 | -7.4 | -1.58 | 27 | ||
2016-07-28 | 2016-06-30 | -6.47 | -6.0 | 0.47 | 7 | ||
2016-04-28 | 2016-03-31 | -6.89 | -6.8 | 0.09 | 1 | ||
2016-02-24 | 2015-12-31 | -5.12 | -4.0 | 1.12 | 21 | ||
2015-10-29 | 2015-09-30 | -8.01 | -6.5 | 1.51 | 18 | ||
2015-07-30 | 2015-06-30 | -7.14 | -6.5 | 0.64 | 8 | ||
2015-04-30 | 2015-03-31 | -7.89 | -8.3 | -0.41 | 5 | ||
2015-02-24 | 2014-12-31 | -8.12 | -7.8 | 0.32 | 3 | ||
2014-11-06 | 2014-09-30 | -8.18 | -8.5 | -0.32 | 3 | ||
2014-07-31 | 2014-06-30 | -9.08 | -8.3 | 0.78 | 8 | ||
2014-05-06 | 2014-03-31 | -7.08 | -9.6 | -2.52 | 35 | ||
2014-03-06 | 2013-12-31 | -11.37 | -21.4 | -10.03 | 88 |
Tandem Diabetes Corporate Management
| Tom Fox | Chief Officer | Profile | |
| Susan Morrison | Chief Admin. Officer | Profile | |
| Mark Novara | Executive Officer | Profile | |
| Ross Sylvia | VP Marketing | Profile | |
| David Esq | Transitional Advisor | Profile | |
| Jordan MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 0.436 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.